Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
Table 1
Baseline demographics of patients with ulcerative colitis (UC) who achieved remission with prednisolone (PSL) or tacrolimus (TAC) and were retrospectively reviewed.
Demography
PSL group ()
TAC group ()
value
Male/female
36/19
22/18
NS
Age (years)
42.4 ± 17.5
43.7 ± 15.6
NS
Duration of UC (years)
5.6 ± 6.6
8.7 ± 1.3
<0.05
Extent of UC, pancolitis/left-sided colitis
48/6/1
24/16/0
NS
Past AZA therapy (yes/no)
35/20
29/11
NS
Clinical activity index (CAI)
11.8 ± 2.6
13.6 ± 2.8
<0.05
Duration of hospital stay (days)
32.5 ± 6.9
26 ± 10.2
<0.05
Total PSL until remission (mg)
702 ± 368
706 ± 354
NS
Discontinuance of PSL after remission (yes/no)
17/38
27/13
<0.05
Baseline Hb (g/dL)
12.3 ± 2.2
12.2 ± 2.5
NS
Baseline CRP (mg/dL)
3.8 ± 4.3
2.3 ± 3.3
NS
Mayo
2.7 ± 0.4
3.0 ± 0.0
<0.05
UCEIS
3.4 ± 1.9
5.1 ± 1.6
<0.05
EAI
12.3 ± 2.3
13.8 ± 2.4
<0.05
Data are mean ± SD or number of patients. AZA, azathioprine; CRP, C-reactive protein; EAI, endoscopic activity index; Hb, hemoglobin; NS, not significant; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.
